Business Wire

IQM

Share
IQM: A New Super-cooled Microwave Source Boosts the Scale-up of Quantum Computers

In a new work published in Nature Electronics, researchers in Finland have developed a circuit that produces the high-quality microwave signals required to control quantum computers while operating at temperatures near absolute zero. This is a key step towards moving the control system closer to the quantum processor, which may make it possible to greatly increase the number of qubits in the processor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005593/en/

One of the factors limiting the size of quantum computers is the mechanism used to control the qubits in quantum processors. This is normally accomplished using a series of microwave pulses, and because quantum processors operate at temperatures near absolute zero, the control pulses are normally brought into the cooled environment via broadband cables from room temperature.

As the number of qubits grows, so does the number of cables needed. This limits the potential size of a quantum processor, because the refrigerators cooling the qubits would have to become larger to accommodate more and more cables while also working harder to cool them down – ultimately a losing proposition.

A research consortium including Aalto University , VTT Technical Research Centre of Finland , and IQM Quantum Computers has now developed a key component of the solution to this conundrum. ‘We have built a precise microwave source that works at the same extremely low temperature as the quantum processors, approximately -273 degrees,’ says the team leader Mikko Möttönen , Professor at Aalto University and VTT Technical Research Centre of Finland and a Co-Founder and Chief Scientist of IQM.

The new microwave source is an on-chip device that can be integrated with a quantum processor. Less than a millimetre in size, it potentially removes the need for high-frequency control cables connecting different temperatures. With this low-power, low-temperature microwave source, it may be possible to use smaller cryostats while still increasing the number of qubits in a processor.

‘Our device produces one hundred times more power than previous versions, which is enough to control qubits and carry out quantum logic operations,’ says Möttönen. ‘It produces a very precise sine wave, oscillating over a billion times per second. As a result, errors in qubits from the microwave source are very infrequent, which is important when implementing precise quantum logic operations.’

However, a continuous-wave microwave source, such as the one produced by this device, cannot be used as is to control qubits. First, the microwaves must be shaped into pulses. The team is currently developing methods to quickly switch the microwave source on and off.

Even without a switching solution to create pulses, an efficient, low-noise, low-temperature microwave source could be useful in a range of quantum technologies, such as quantum sensors.

‘In addition to quantum computers and sensors, the microwave source can act as a clock for other electronic devices. It can keep different devices in the same rhythm, allowing them to induce operations for several different qubits at the desired instant of time,’ explains Möttönen.

The theoretical analysis and the initial design were carried out by Juha Hassel and others at VTT. Hassel, who started this work at VTT, is currently the head of engineering and development at IQM Quantum Computers, Pan-European leader in quantum computers. The device was then built at VTT and operated by postdoctoral research Chengyu Yan and his colleagues at Aalto University using the OtaNano research infrastructure. Yan is currently an associate professor at Huazhong University of Science and Technology, China. The teams involved in this research are part of the Academy of Finland Centre of Excellence in Quantum Technology (QTF) and the Finnish Quantum Institute (InstituteQ).

Original research paper

Chengyu Yan, Juha Hassel, Visa Vesterinen, Jinli Zhang, Joni Ikonen, Leif Grönberg, Jan Goetz and Mikko Möttönen, A low-noise on-chip coherent microwave source , Nature Electronics, DOI:10.1038/s41928-021-00680-z (2021)

https://doi.org/10.1038/s41928-021-00680-z (link opens after embargo ceases)

Preprint available at any time: https://arxiv.org/pdf/2103.07617

More pictures in the material bank : https://materialbank.aalto.fi/l/sjcg87sHxFfR

About IQM Quantum Computers

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich and Espoo and employs over 130 people. More information: www.meetiqm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye